MK-8835/PF-04971729 vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Inclusion Criteria:

- Diagnosis of T2DM in accordance to American Diabetes Association guidelines

- On metformin monotherapy or metformin in combination with a single allowable
anti-hyperglycemic agent (AHA), dipeptidyl peptidase-4 (DPP-4) inhibitors,
meglitinides, or alpha-glucosidase inhibitors) prior to study participation.

- Body Mass Index (BMI) ≥18.0 kg/m^2

- Male or female not of reproductive potential

- If a female of reproductive potential, agree to remain abstinent or to use (or have
their partner use) 2 acceptable combinations of birth control while participating in
the trial and for 14 days after the last use of study drug.

Exclusion Criteria:

- History or presence of type 1 diabetes mellitus or a history of ketoacidosis

- History of other specific types of diabetes (eg, genetic syndromes, secondary
pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and
post-organ transplant).

- A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2
(SGLT2) inhibitor

- Use of the following prohibited therapeutic agents within 12 weeks of study
participation: insulin, injectable anti-hyperglycemic agents, pioglitazone or
rosiglitazone, another SGLT2 inhibitor, bromocriptine (Cycloset®), colesevelam
(Welchol®), and any other non-approved anti-hyperglycemic therapy

- Known hypersensitivity or intolerance to metformin or glimepiride

- On a weight-loss program or medication or medication associated with weight changes
and is not weight-stable (>=5% change in body weight in the last 6 months)

- History of bariatric surgery less than 12 months prior to study participation

- History of myocardial infarction, unstable angina, arterial revascularization,
stroke, transient ischemic attack, or New York Heart Association (NYHA) functional
class III-IV heart failure within 3 months of study participation

- Active, obstructive uropathy or an indwelling urinary catheter

- A history of malignancy ≤5 years prior to study participation, except for adequately
treated basal or squamous cell skin cancer or in situ cervical cancer

- Known history of Human Immunodeficiency Virus (HIV)

- Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells

- A medical history of active liver disease (other than non-alcoholic hepatic
steatosis), including chronic active hepatitis B or C (assessed by medical history),
primary biliary cirrhosis, or symptomatic gallbladder disease

- Any clinically significant malabsorption condition

- Being treated for hyperthyroidism, or on thyroid replacement therapy that has not
been at a stable dose for at least 6 weeks prior to study participation

- Previous randomization in a study with ertugliflozin

- Participation in other studies involving investigational drug(s) within 30 days of
study participation and/or during the pre-randomization period

- A surgical procedure within 6 weeks prior to study participation or planned major
surgery during the trial

- A positive urine pregnancy test

- Pregnant or breast-feeding, or expecting to conceive during the trial, including 14
days following the last dose of study drug

- Undergoing hormonal therapy in preparation to donate eggs during the period of the
trial, including 14 days following the last dose of study drug

- Consumption of more than 2 alcoholic drinks per day or engages in binge drinking

- Donation of blood or blood products within 6 weeks of study participation or plans to
donate blood or blood products at any time during the trial